Clinical trial study on expanding new indications of IMM01 project

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first Fc fusion protein drug targeting human CD47 (project number: IMM01) in China was accepted by NMPA for clinical trial application (IND) for new indications (MM, AML and MDS). This is......

2020-11-21

The patent of IMM0306 of ImmuneOnco was authorized by China Intellectual Property Office

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the IMM0306 project of the company has recently obtained the invention patent authorization of the China Intellectual Property Office (China patent application No.: CN201710151979.6). Meanwhi......

2020-09-15

The fifth anniversary of ImmuneOnco and the completion ceremony of the antibody drug research and development center were held successfully

On July 31, 2020, the fifth anniversary of ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. and the completion ceremony of antibody drug R & D center were successfully held in building 47, Lane 908, Ziping road. ImmuneOnco Biopharmaceuticals (Shanghai......

2020-08-05

​The world's first bispecific antibody drug simultaneously targeting CD47 and CD20 has been approved clinical trial by NMPA

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the bispecific antibody drug (project number: IMM0306) independently developed and simultaneously targeting CD47 and CD20 has recently obtained the clinical trial license of NMPA (Acceptance......

2020-07-09

The second general meeting of shareholders of ImmuneOnco was successfully held

The founder and chairman of ImmuneOnco, Dr. Tian Wenzhi, delivered a speech on the spot. He reviewed the company's development history and the achievements achieved in stages, summarized the work of the company in 2019, and introduced the new drug...

2020-06-14